Table 3.
Clinical measures and end points
| Transdermal fentanyl (N=119) |
Oral oxycodone-naloxone (N=191) |
p-value | |
|---|---|---|---|
| Responders | 75.3% (3.7) | 82.9% (2.9) | 0.11 |
| Clinical success | 27.8% (4.4) | 36.5% (3.4) | 0.12 |
| Starting opioid dose (mg/day)a | 53.0 (1.3) | 25.4 (1.0) | <0.0001 |
| Final dose (mg/day)a | 113.6 (4.9) | 44.5 (3.9) | <0.0001 |
| Mean dose increasea | 2.5 (1.8) | 0.4 (1.4) | <0.0001 |
| OEI >5%a | 37.9% (4.1) | 19.3% (3.2) | <0.0001 |
| Patients requiring additional opioids | 37.1% (4.4) | 28.2% (3.4) | 0.12 |
| Patients requiring adjuvant drugs | 83.7% (3.5) | 82.4% (2.8) | 0.78 |
| Switches | 14.1% (3.1) | 10.6% (2.4) | 0.37 |
| Premature discontinuations due to ADRs | 2.8% (1.2) | 0.9% (0.9) | 0.22 |
| Severe constipation | 32.6% (4.2) | 24.7% (3.3) | 0.15 |
Notes:
Values are percentage or number (standard error);
a
around-the-clock daily doses (as oral morphine-equivalent daily dose).
Abbreviations: ADRs, adverse drug reactions; OEI, opioid escalation index.